Abstract
Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-lactamase inhibitor. In studies in healthy volunteers, the pharmacokinetics of piperacillin combined with tazobactam were similar to those of piperacillin alone. In contrast, tazobactam administered with piperacillin achieved higher plasma concentrations and had a longer half-life than tazobactam administered alone. Intravenous infusion of 4.0 g piperacillin with 0.5 g tazobactam over 5 min resulted in mean maximum plasma concentrations of 380 μg piperacillin/ml and 35.3 μg tazobactam/ml; half-lives were 1.14 h for piperacillin and 0.92 h for tazobactam. Within 30 min of infusion, piperacillin/tazobactam achieves 16–85% of plasma concentrations in skin, muscle, lung, gallbladder, and intestinal mucosa. Plasma and tissue levels remain above the MIC90s of major pathogens for 2 h post administration. These findings show that piperacillin/tazobactam is a truly synergistic combination which can be expected to be effective in treating a wide variety of infections in the clinical setting.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Gutman L, Kitzis MD, Yamabe S, Acar JF (1986) Comparative evaluation of a new β-lactamase inhibitor, YTR 830, combined with different β-lactam antibiotics against bacteria harboring known β-lactamases. Antimicrob Agents Chemother 29:955–957
Jacobs MR, Aronoff SC, Johenning S, Yamabe S (1986a) Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined β-lactamase-producing aerobic gramnegative bacilli. Antimicrob Agents Chemother 29:980–985
Jacobs MR, Aronoff SC, Johenning S, Yamabe S (1986b) Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistentEnterobacteriaceae and pseudomonas. J Antimicrob Chemother 18:177–184
Kern W, Kennedy SL, Sachdeva M, Sande ER, Gunderson D, Täuber MG (1990) Evaluation of piperacillin-tazobactam in experimental meningitis caused by a β-lactamase-producing strain of K1-positiveEscherichia coli. Antimicrob Agents Chemother 34:697–700
Gould IM, Ansari A, Harvey G, Douglas JG, Smith CC, Reid TM (1991) Piperacillin/tazobactam in the treatment of serious acute soft tissue infection. Drugs Exp Clin Res 17:187–190
Kinzig M, Sörgel F, Brismar B, Nord CE (1992) Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother 36:1997–2004
Muth P, Kinzig M, Kujath P, Sörgel F (1991) Determination of tazobactam levels in human plasma and tissue using a HPLC column switching technique. J Chemother [Suppl 4]:227–228
Fortner CL, Finley RS, Schimpff SC (1982) Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Pharmacotherapy 2:287–299
Holmes B, Richards DM, Brogden RN, Heel RC (1984) Piperacillin — a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 28:375–425
Seelmann R, Sörgel F, Wiesemann HG, Grüner A, Stephan U (1987) New aspects of piperacillin's pharmacokinetics in man. Proceedings of the Fifteenth International Congress of Chemotherapy, Istanbul, Turkey, 1987. In: Kuemmerle HP (ed) Progress of antimicrobial and anticancer chemotherapy. Ecomed, Landsberg/Lech, Germany, pp 961–963
Sörgel F, Stephan U, Lang E, Geldmacher-von Mallinckrodt M, Seelmann R, Wiesemann HG (1986) Pharmacokinetik von Piperacillin im Vergleich. In: Adam D, Knothe H, Stille W (eds) In Paul-Ehrlich-Gesellschaft. Piperacillin, Fortschritte der antimikrobiellen antineoplastischen Chemotherapie FAC 5-6. Futuramed, Munich, Germany, pp 921–937
Sörgel F, Seelmann R, Stephan U (1988) Comparative pharmacokinetics of apalcillin, mezlocillin, and piperacillin in healthy volunteers. Proceedings of the First Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Munich, Germany, 1987. In: Adam D, Hiddemann W (eds) Paul-Ehrlich-Gesellschaft. J Chemother Inf Dis Malig ZAC 6 [Suppl 1], Futuramed, Munich, Germany, pp 157–158
Cheung WK, Greene DS, Kuye O, Shin KJ, Tonelli AP, Houston A et al (1988a) Pharmacokinetics of YTR 830 and piperacillin after intravenous coadministration. Proceedings of the Sixth Mediterranean Congress of Chemotherapy, Taormina, Italy, 1988. Abstr. 159
Cheung WK, Greene DS, Kuye O, Smith MPJ, Holder A, Fernandez P et al. (1988b) Pharmacokinetics of YTR 830 in healthy human subjects. Proceedings of the Sixth Mediterranean Congress of Chemotherapy, Taormina, Italy, 1988. Abstr. 158
Ganes D, Batra V, Faulkner R, Greene D, Haynes J, Kuye O et al (1991) Effect of probenecid on the pharmacokinetics of piperacillin and tazobactam in healthy volunteers. Proceedings of the Sixth Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Washington DC. Pharmaceut Res 8:S-299. Abstr. PPDM 8293
Weiss W, Jacobus N, Petersen P, Testa R, Tally F (1989) Bactericidal and β-lactamase inhibitory activity of piperacillin/tazobactam. In: Piperacillin and tazobactam. Proceedings of the Sixteenth International Congress of Chemotherapy, Jersualem, Israel, June 11–16, 1989
Wu WH, Greene DS, Kuye O et al (1989) Pharmacokinetic observations with piperacillin/tazobactam and their relevance to dosage decisions. In: Piperacillin and tazobactam. Proceedings of the Sixteenth International Congress of Chemotherapy, Jerusalem, Israel, June 11–16, 1989
Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A et al (1992) Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharm Ther 51:32–41
Wu WH, Greene DS, Kuye O, Ruffner A, Höffler D, Haynes J et al (1991) Pharmacokinetics of piperacillin/tazobactam (4/1) after a single infusion in renal impaired patients. Sixth Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Washington, DC. Pharmaceutical Res 8:S-303. Abstr. PPDM 8357
Lathia C, Sia L, Lanc R, Greene D, Kuye O, Batra V et al (1991 b) Pharmacokinetics of piperacillin/tazobactam IV with and without tobramycin IV in healthy adult male volunteers. Sixth Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Washington DC. Pharmaceut Res 8:S-303. Abstr. PPDM 8310
Tulkens PM (1990) Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data. Proceedings of the Symposium in Stockholm, Sweden, Bohusläningens Boktryckeri AB, Uddevalla, Sweden, pp 249–257
Drusano GL (1991) Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis [Suppl 74]:235–248
American Cyanamid, Data on File
Sörgel F, Kinzig M, Naber KG (1993) Physiological disposition of macrolides. In: Bryskier A, Butzler JP, Neu HC, Tulkens PM (eds) Macrolides-chemistry, pharmacology and clinical uses. Blackwell, Paris, France, pp 421–435
Kinzig M, Sörgel F, Naber KG, Müller C (Oct 11–14, 1992) Penetration of erythromycin ethylsuccinate (EES), erythromycin (E), and new macrolides (MAC) into extracellular fluids (ECF) — a tool to study unresolved questions of macrolide pharmacokinetics. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Ca (USA), Abstr. 217
Kinzig M, Muth P, Kujath P, Ebert J, Mahr G, Sörgel F et al (1991 a) Pharmacokinetics and tissue penetration of tazobactam/piperacillin in man. Proceedings of the Seventeenth International Congress of Chemotherapy, Berlin, Germany, Abstr. 949
Kinzig M, Sörgel F, Naber KG, Kujath P, Nord CE, Brismar B et al (1991 b) Tissue penetration of piperacillin/tazobactam. Proceedings of the thirty-first Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago Illinois, Abstr. 862. American Society for Microbiology, Washington, DC
Naber KG, Sörgel F, Kinzig M, Weigel D (1991) Penetration of piperacillin/tazobactam into prostatic tissue and secretion of elderly patients. Proceedings of the Seventeenth International Congress of Chemotherapy, Berlin, Germany, Abstr. 951
Wise R, Logan M, Cooper M, Andrews JM (1991) Pharmacokinetics macokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 35:1081–1084
Fass RJ, Prior RB (1989) Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 33:1268–1274
Sörgel F, Kinzig M (1993) The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 31 [Suppl A]:39–60
Author information
Authors and Affiliations
Additional information
Dedicated to Peter Nickel, PhD., Professor and Chairman of the Department of Pharmaceutical Chemistry at the University of Bonn on the occasion of his 60th birthday
Rights and permissions
About this article
Cite this article
Sörgel, F., Kinzig, M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med 20 (Suppl 3), S14–S20 (1994). https://doi.org/10.1007/BF01745246
Issue Date:
DOI: https://doi.org/10.1007/BF01745246